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G lycemic management in type 2 di-abetes mellitus has become increas-ingly complex and, to some extent,
controversial, with a widening array of
pharmacological agents now available (1–5),
mounting concerns about their potential
adverse effects and new uncertainties re-
garding the beneﬁts of intensive glycemic
control on macrovascular complications
(6–9). Many clinicians are therefore per-
plexed as to the optimal strategies for their
patients. As a consequence, the American
DiabetesAssociation (ADA) and theEuropean
Association for the Study of Diabetes (EASD)
convened a joint task force to examine the
evidence and develop recommendations for
antihyperglycemic therapy in nonpregnant
adults with type 2 diabetes. Several guide-
line documents have been developed by
members of these two organizations (10)
and by other societies and federations
(2,11–15). However, an update was
deemed necessary because of contemporary
information on the beneﬁts/risks of glycemic
control, recent evidence concerning efﬁcacy
and safety of several new drug classes
(16,17), the withdrawal/restriction of others,
and increasing calls for a move toward more
patient-centered care (18,19).
This statement has been written in-
corporating the best available evidence
and, where solid support does not exist,
using the experience and insight of the
writing group, incorporating an extensive
review by additional experts (acknowl-
edged below). The document refers to
glycemic control; yet this clearly needs to
be pursued within a multifactorial risk
reduction framework. This stems from the
fact that patients with type 2 diabetes are
at increased risk of cardiovascular morbid-
ity and mortality; the aggressive manage-
ment of cardiovascular risk factors (blood
pressure and lipid therapy, antiplatelet
treatment, and smoking cessation) is likely
to have even greater beneﬁts.
These recommendations should be
considered within the context of the needs,
preferences, and tolerances of each patient;
individualization of treatment is the cor-
nerstone of success. Our recommenda-
tions are less prescriptive than and not as
algorithmic as prior guidelines. This fol-
lows from the general lack of comparative-
effectiveness research in this area. Our
intent is therefore to encourage an appre-
ciation of the variable and progressive
nature of type 2 diabetes, the speciﬁc role
of each drug, the patient and disease
factors that drive clinical decisionmaking
(20–23), and the constraints imposed by
age and comorbidity (4,6). The implemen-
tation of these guidelines will require
thoughtful clinicians to integrate current
evidence with other constraints and im-
peratives in the context of patient-speciﬁc
factors.
PATIENT-CENTERED
APPROACHdEvidence-based advice
depends on the existence of primary
source evidence. This emerges only
from clinical trial results in highly selected
patients, using limited strategies. It does
not address the range of choices available,
or the order of use of additional therapies.
Even if such evidence were available, the
data would show median responses and
not address the vital question of who
responded to which therapy and why (24).
Patient-centered care is deﬁned as an ap-
proach to “providing care that is respectful
of and responsive to individual patient
preferences, needs, and values and ensur-
ing that patient values guide all clinical de-
cisions” (25). This should be the organizing
principle underlying health care for indi-
viduals with any chronic disease, but given
our uncertainties in terms of choice or se-
quence of therapy, it is particularly appro-
priate in type 2 diabetes. Ultimately, it is
patients who make the ﬁnal decisions re-
garding their lifestyle choices and, to some
degree, the pharmaceutical interventions
they use; their implementation occurs in
the context of the patients’ real lives and
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relies on the consumption of resources
(both public and private).
Patient involvement in the medical
decision making constitutes one of the
core principles of evidence-based medi-
cine, which mandates the synthesis of best
available evidence from the literature with
the clinician’s expertise and patient’s own
inclinations (26).During the clinical encoun-
ter, the patient’s preferred level of involve-
ment should be gauged and therapeutic
choices explored, potentially with the uti-
lization of decision aids (21). In a shared
decision-making approach, clinician and
patient act as partners, mutually exchanging
information and deliberating on options, in
order to reach a consensus on the therapeu-
tic course of action (27). There is good ev-
idence supporting the effectiveness of this
approach (28). Importantly, engaging pa-
tients in health care decisions may enhance
adherence to therapy.
BACKGROUND
Epidemiology and health care
impact
Both the prevalence and incidence of type 2
diabetes are increasing worldwide, particu-
larly in developing countries, in conjunction
with increased obesity rates and westerni-
zation of lifestyle. The attendant economic
burden for health care systems is skyrocket-
ing, owing to the costs associated with treat-
ment and diabetes complications. Type 2
diabetes remains a leading cause of car-
diovascular disorders, blindness, end-stage
renal failure, amputations, and hospitaliza-
tions. It is also associatedwith increased risk
of cancer, serious psychiatric illness, cogni-
tive decline, chronic liver disease, acceler-
ated arthritis, and other disabling or deadly
conditions. Effective management strategies
are of obvious importance.
Relationship of glycemic control
to outcomes
It is well established that the risk of micro-
vascular and macrovascular complications
is related to glycemia, as measured by
HbA1c; this remains a major focus of ther-
apy (29). Prospective randomized trials
have documented reduced rates of micro-
vascular complications in type 2 diabetic
patients treated to lower glycemic targets.
In the UK Prospective Diabetes Study
(UKPDS) (30,31), patients with newly di-
agnosed type 2 diabetes were randomized
to two treatment policies. In the standard
group, lifestyle intervention was the main-
stay with pharmacological therapy used
only if hyperglycemia became severe. In the
more intensive treatment arm, patients were
randomly assigned to either a sulfonylurea
or insulin, with a subset of overweight
patients randomized to metformin. The
overall HbA1c achieved was 0.9% lower
in the intensive policy group compared
with the conventional policy arm (7.0%
vs. 7.9%). Associatedwith this difference in
glycemic controlwas a reduction in the risk
of microvascular complications (retinopa-
thy, nephropathy, neuropathy) with inten-
sive therapy. A trend toward reduced rates
of myocardial infarction in this group did
not reach statistical signiﬁcance (30). By
contrast, substantially fewer metformin-
treated patients experienced myocardial
infarction, diabetes-related and all-cause
mortality (32), despite a mean HbA1c only
0.6% lower than the conventional policy
group. The UKPDS 10-year follow-up
demonstrated that the relative beneﬁt of
having been in the intensive management
policy group was maintained over a de-
cade, resulting in the emergence of statisti-
cally signiﬁcant beneﬁts on cardiovascular
disease (CVD) endpoints and totalmortality
in those initially assigned to sulfonylurea/
insulin, and persistence of CVD beneﬁts
with metformin (33), in spite of the fact
that the mean HbA1c levels between the
groups converged soon after the ran-
domized component of the trial had
concluded.
In 2008, three shorter-term studies
[Action to Control Cardiovascular Risk in
Diabetes (ACCORD) (34), Action in Dia-
betes and Vascular Disease: Preterax and
Diamicron Modiﬁed-Release Controlled
Evaluation (ADVANCE) (35), Veterans Af-
fairs Diabetes Trial (VADT) (36)] reported
the effects of two levels of glycemic control
on cardiovascular end points in middle-
aged and older individuals with well-
established type 2 diabetes at high risk for
cardiovascular events. ACCORD and VADT
aimed for an HbA1c,6.0% using complex
combinations of oral agents and insulin.
ADVANCE aimed for an HbA1c #6.5%
using a less intensive approach based on
the sulfonylurea gliclazide. None of the
trials demonstrated a statistically signif-
icant reduction in the primary combined
cardiovascular end points. Indeed, in
ACCORD, a 22% increase in totalmortality
with intensive therapy was observed,
mainly driven by cardiovascular mortality.
An explanation for this ﬁnding has re-
mained elusive, although rates of hypogly-
cemia were threefold higher with intensive
treatment. It remains unclear, however, if
hypoglycemia was responsible for the ad-
verse outcomes, or if other factors, such as
more weight gain, or simply the greater
complexity of therapy, contributed. There
were suggestions in these trials that patients
without overt CVD, with shorter duration
of disease, and lower baseline HbA1c,
beneﬁted from the more intensive strat-
egies. Modest improvements in some
microvascular end points in the studies
were likewise demonstrated. Finally, a
meta-analysis of cardiovascular out-
comes in these trials suggested that every
HbA1c reduction of ;1% may be associ-
ated with a 15% relative risk reduction in
nonfatal myocardial infarction, but
without beneﬁts on stroke or all-cause
mortality (36).
Overview of the pathogenesis of
type 2 diabetes
Any rise in glycemia is the net result of
glucose inﬂux exceeding glucose outﬂow
from the plasma compartment. In the fast-
ing state, hyperglycemia is directly related
to increased hepatic glucose production.
In the postprandial state, further glucose
excursions result from the combination
of insufﬁcient suppression of this glucose
output and defective insulin stimulation
of glucose disposal in target tissues, mainly
skeletal muscle. Once the renal tubular
transport maximum for glucose is excee-
ded, glycosuria curbs, though does not
prevent, further hyperglycemia.
Abnormal islet cell function is a key
and requisite feature of type 2 diabetes. In
early disease stages, insulin production is
normal or increased in absolute terms,
but disproportionately low for the degree
of insulin sensitivity, which is typically
reduced. However, insulin kinetics, such
as the ability of the pancreatic b-cell to
release adequate hormone in phase with
rising glycemia, are profoundly compro-
mised. This functional islet incompetence
is the main quantitative determinant of
hyperglycemia (37) and progresses over
time. In addition, in type 2 diabetes, pan-
creatic a-cells hypersecrete glucagon, fur-
ther promoting hepatic glucose production
(38). Importantly, islet dysfunction is not
necessarily irreversible. Enhancing insulin
action relieves b-cell secretory burden, and
any intervention that improves glycemiad
from energy restriction to, most strikingly,
bariatric surgerydcan ameliorate b-cell
dysfunction to an extent (39). More re-
cently recognized abnormalities in the in-
cretin system (represented by the gut
hormones, glucagon-like peptide 1 [GLP-1],
and glucose-dependent insulinotropic
peptide [GIP]) are also found in type 2
diabetes, but it remains unclear whether
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these constitute primary or secondary de-
fects (40). In most patients with type 2
diabetes, especially the obese, insulin re-
sistance in target tissues (liver, muscle,
adipose tissue, myocardium) is a promi-
nent feature. This results in both glucose
overproduction and underutilization.
Moreover, an increaseddelivery of fatty acids
to the liver favors their oxidation, which
contributes to increased gluconeogenesis,
whereas the absolute overabundance of lip-
ids promotes hepatosteatosis (41).
Antihyperglycemic agents are directed
at one or more of the pathophysiological
defects of type 2 diabetes, or modify
physiological processes relating to appetite
or to nutrient absorption or excretion.
Ultimately, type 2 diabetes is a disease
that is heterogeneous in both pathogenesis
and in clinical manifestationda point to be
considered when determining the optimal
therapeutic strategy for individual patients.
ANTIHYPERGLYCEMIC
THERAPY
Glycemic targets
The ADA’s “Standards of Medical Care in
Diabetes” recommends lowering HbA1c
to ,7.0% in most patients to reduce the
incidence of microvascular disease (42).
This can be achieved with a mean plasma
glucose of;8.3–8.9 mmol/L (;150–160
mg/dL); ideally, fasting and premeal glu-
cose should bemaintained at,7.2mmol/L
(,130 mg/dL) and the postprandial glu-
cose at ,10 mmol/L (,180 mg/dL).
More stringent HbA1c targets (e.g., 6.0–
6.5%) might be considered in selected
patients (with short disease duration, long
life expectancy, no signiﬁcant CVD) if this
can be achieved without signiﬁcant hypo-
glycemia or other adverse effects of treat-
ment (20,43). Conversely, less stringent
HbA1c goalsde.g., 7.5–8.0% or even
slightly higherdare appropriate for pa-
tientswith ahistory of severe hypoglycemia,
limited life expectancy, advanced complica-
tions, extensive comorbid conditions and
those inwhom the target is difﬁcult to attain
despite intensive self-management educa-
tion, repeated counseling, and effective
doses of multiple glucose-lowering agents,
including insulin (20,44).
The accumulated results from the
aforementioned type 2 diabetes cardio-
vascular trials suggest that not everyone
beneﬁts from aggressive glucose man-
agement. It follows that it is important to
individualize treatment targets (5,34–36).
The elements that may guide the clinician
in choosing an HbA1c target for a speciﬁc
patient are shown in Fig. 1. As mentioned
earlier, the desires and values of the pa-
tient should also be considered, since the
achievement of any degree of glucose con-
trol requires active participation and com-
mitment (19,23,45,46). Indeed, any target
could reﬂect an agreement between pa-
tient and clinician. An important related
concept is that the ease with which more
intensive targets are reached inﬂuences
treatment decisions; logically, lower tar-
gets are attractive if they can be achieved
with less complex regimens and no or
minimal adverse effects. Importantly, uti-
lizing the percentage of diabetic patients
who are achieving an HbA1c ,7.0% as a
quality indicator, as promulgated by vari-
ous health care organizations, is inconsis-
tentwith the emphasis on individualization
of treatment goals.
Therapeutic options
Lifestyle. Interventions designed to im-
pact an individual’s physical activity lev-
els and food intake are critical parts of
type 2 diabetes management (47,48). All
patients should receive standardized gen-
eral diabetes education (individual or
group, preferably using an approved cur-
riculum), with a speciﬁc focus on dietary
interventions and the importance of in-
creasing physical activity. While encourag-
ing therapeutic lifestyle change is important
at diagnosis, periodic counseling should
also be integrated into the treatment
program.
Weight reduction, achieved through
dietary means alone or with adjunctive
medical or surgical intervention, improves
glycemic control and other cardiovascular
risk factors.Modestweight loss (5–10%)con-
tributes meaningfully to achieving improved
glucose control. Accordingly, establishing a
goal of weight reduction, or at least weight
maintenance, is recommended.
Dietary advice must be personalized
(49). Patients should be encouraged to eat
healthy foods that are consistent with the
prevailing population-wide dietary rec-
ommendations and with an individual’s
preferences and culture. Foods high in ﬁber
(such as vegetables, fruits,whole grains, and
Figure 1dDepiction of the elements of decision making used to determine appropriate efforts to
achieve glycemic targets. Greater concerns about a particular domain are represented by in-
creasing height of the ramp. Thus, characteristics/predicaments toward the left justify more
stringent efforts to lower HbA1c, whereas those toward the right are compatible with less
stringent efforts. Where possible, such decisions should be made in conjunction with the patient,
reﬂecting his or her preferences, needs, and values. This “scale” is not designed to be applied
rigidly but to be used as a broad construct to help guide clinical decisions. Adapted with per-
mission from Ismail-Beigi et al. (20).
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legumes), low-fat dairy products, and fresh
ﬁsh should be emphasized. High-energy
foods, including those rich in saturated
fats, and sweet desserts and snacks should
be eaten less frequently and in lower
amounts (50–52). Patients who eventually
lose and keep weight off usually do so after
numerous cycles of weight loss and relapse.
The health care team should remain non-
judgmental but persistent, revisiting and
encouraging therapeutic lifestyle changes
frequently, if needed.
As much physical activity as possible
should be promoted, ideally aiming for at
least 150 min/week of moderate activity
including aerobic, resistance, and ﬂexi-
bility training (53). In older individuals,
or those with mobility challenges, so
long as tolerated from a cardiovascular
standpoint, any increase in activity level
is advantageous.
At diagnosis, highly motivated pa-
tients withHbA1c already near target (e.g.,
,7.5%) could be given the opportunity
to engage in lifestyle change for a period
of 3–6 months before embarking on
pharmacotherapy (usually metformin).
Those with moderate hyperglycemia or
in whom lifestyle changes are anticipated
to be unsuccessful should be promptly
started on an antihyperglycemic agent
(also usually metformin) at diagnosis,
which can later be modiﬁed or possibly
discontinued if lifestyle changes are suc-
cessful.
Oral agents and noninsulin injectables.
Important properties of antihyperglyce-
mic agents that play a role in the choice of
drug(s) in individual patients are summa-
rized in Table 1. Ultimately, the aims of
controlling glycemia are to avoid acute
osmotic symptoms of hyperglycemia, to
avoid instability in blood glucose over
time, and to prevent/delay the develop-
ment of diabetes complications without
adversely affecting quality of life. Infor-
mation on whether speciﬁc agents have
this ability is incomplete; an answer to
these questions requires long-term, large-
scale clinical trialsdnot available for most
drugs. Effects on surrogate measures for
glycemic control (e.g., HbA1c) generally
reﬂect changes in the probability of de-
veloping microvascular disease but not
necessarily macrovascular complications.
Particularly from a patient standpoint,
stability of metabolic control over time
may be another speciﬁc goal.
Metformin, a biguanide, remains the
most widely used ﬁrst-line type 2 diabetes
drug; its mechanism of action predomi-
nately involves reducing hepatic glucose
production (54,55). It is generally consid-
ered weight-neutral with chronic use and
does not increase the risk of hypoglycemia.
Metformin is associated with initial gastro-
intestinal side effects, and caution is ad-
vised to avoid its use in patients at risk for
lactic acidosis (e.g., in advanced renal in-
sufﬁciency, alcoholism), a rare complica-
tion of therapy. As noted earlier, there
may be some cardiovascular beneﬁts
from this drug, but the clinical trial data
are not robust.
The oldest oral agent class is the sulfo-
nylurea insulin secretagogues. Through
the closure of ATP-sensitive potassium
channels on b-cells, these drugs stimulate
insulin release (56).While effective in con-
trolling glucose levels, their use is associ-
ated with modest weight gain and risk of
hypoglycemia. In addition, studies have
demonstrated a secondary failure rate
that may exceed other drugs, ascribed to
an exacerbation of islet dysfunction (57).
Shorter-acting secretagogues, the megliti-
nides (or glinides), stimulate insulin re-
lease through similar mechanisms but
may be associated with less hypoglycemia
(58). They require more frequent dosing,
however.
Thiazolidinediones (TZDs) are per-
oxisome proliferator–activated receptor g
activators (59) that improve insulin sen-
sitivity in skeletal muscle and reduce he-
patic glucose production (54,55). They
do not increase the risk of hypoglycemia
andmay be more durable in their effective-
ness than sulfonylureas and metformin
(57). Pioglitazone appeared to have a mod-
est beneﬁt on cardiovascular events as a
secondary outcome in one large trial in-
volving patients with overt macrovascular
disease (60). Another agent of this class,
rosiglitazone, is no longer widely available
owing to concerns of increased myocardial
infarction risk (61). Pioglitazone has re-
cently been associated with a possible in-
creased risk of bladder cancer (62).
Recognized side effects of TZDs include
weight gain, ﬂuid retention leading to
edema and/or heart failure in predisposed
individuals, and increased risk of bone
fractures (57,60).
Drugs focused on the incretin system
have been introduced more recently (63).
The injectable GLP-1 receptor agonists
mimic the effects of endogenous GLP-1,
thereby stimulating pancreatic insulin se-
cretion in a glucose-dependent fashion,
suppressing pancreatic glucagon output,
slowing gastric emptying, and decreasing
appetite. Their main advantage is weight
loss, which is modest in most patients but
can be signiﬁcant in some. A limiting side
effect is nausea and vomiting, particularly
early in the course of treatment. Concerns
regarding an increased risk of pancreatitis
remain unresolved. The oral dipeptidyl
peptidase 4 (DPP-4) inhibitors enhance
circulating concentrations of active
GLP-1 and GIP (64). Their major effect
appears to be in the regulation of insulin
and glucagon secretion; they are weight
neutral. Typically, neither of the incretin-
based classes cause hypoglycemia by
themselves.
Two agents that are used infrequently
in theU.S. andEurope are thea-glucosidase
inhibitors (AGIs), which retard gut carbohy-
drate absorption (65), and colesevelam, a
bile acid sequestrant whose mechanism of
glucose-lowering action remains poorly
understood and whose major additional
beneﬁt is LDL-cholesterol reduction (66).
Both have gastrointestinal effects, mainly
ﬂatulence with AGIs and constipation
with colesevelam. The dopamine agonist
bromocriptine is only available in the U.S.
as an antihyperglycemic agent (67). Its
mechanism of action and precise role
are unclear. The amylin agonist, pramlintide,
is typically reserved for patients treated
with intensive insulin therapy, usually in
type 1 diabetes mellitus; it decreases post-
prandial glucose excursions by inhibiting
glucagon secretion and slowing gastric
emptying (68).
The glucose-lowering effectiveness of
noninsulin pharmacological agents is said
to be high for metformin, sulfonylureas,
TZDs, and GLP-1 agonists (expected
HbA1c reduction ;1.0–1.5%) (1,69,70),
and generally lower for meglitinides,
DPP-4 inhibitors, AGIs, colesevelam,
and bromocriptine (;0.5–1.0%). How-
ever, older drugs have typically been
tested in clinical trial participants with
higher baseline HbA1c, which is itself as-
sociated with greater treatment emergent
glycemic reductions, irrespective of ther-
apy type. In head-to-head studies, any
differential effects on glucose control are
small. So agent- and patient-speciﬁc prop-
erties, such as dosing frequency, side-effect
proﬁles, cost, and other beneﬁts often
guide their selection.
Insulin. Due to the progressive b-cell
dysfunction that characterizes type 2 di-
abetes, insulin replacement therapy is fre-
quently required (71). Importantly, most
patients maintain some endogenous insu-
lin secretion even in late stages of disease.
Accordingly, the more complex and in-
tensive strategies of type 1 diabetes are
not typically necessary (72).
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Ideally, the principle of insulin use is
the creation of as normal a glycemic proﬁle
as possible without unacceptable weight
gain or hypoglycemia (73). As initial ther-
apy, unless the patient is markedly hyper-
glycemic and/or symptomatic, a “basal”
insulin alone is typically added (74). Basal
insulin provides relatively uniform insulin
coverage throughout the day and night,
mainly to control blood glucose by sup-
pressing hepatic glucose production in
between meals and during sleep. Either
intermediate-acting (neutral protamine
Hagedorn [NPH]) or long-acting (insulin
glargine [A21Gly,B31Arg,B32Arg hu-
man insulin] or insulin detemir [B29Lys
(´-tetradecanoyl),desB30 human insulin])
formulations may be used. The latter two
are associated with modestly less overnight
hypoglycemia (insulin glargine, insulin de-
temir) than NPH and possibly slightly less
weight gain (insulin detemir), but are
more expensive (75,76). Of note, the dos-
ing of these basal insulin analogsmaydiffer,
with most comparative trials showing a
higher average unit requirement with insu-
lin detemir (77).
Although the majority of patients
with type 2 diabetes requiring insulin
therapy can be successfully treated with
basal insulin alone, some, because of pro-
gressive diminution in their insulin secre-
tory capacity, will require prandial insulin
therapy with shorter-acting insulins. This
is typically provided in the form of the
rapid insulin analogs, insulin lispro
(B28Lys,B29Pro human insulin), insulin
aspart (B28Asp human insulin), or insulin
glulisine (B3Lys,B29Glu human insulin),
which may be dosed just before the meal.
They result in better postprandial glucose
control than the less costly human regular
insulin, whose pharmacokinetic proﬁle
makes it less attractive in this setting.
Ideally, an insulin treatment program
should be designed speciﬁcally for an in-
dividual patient, to match the supply of
insulin to his or her dietary/exercise hab-
its and prevailing glucose trends, as revealed
throughself-monitoring.Anticipatedglucose-
lowering effects should be balanced with
the convenience of the regimen, in the
context of an individual’s speciﬁc therapy
goals (Fig. 1).
Proper patient education regarding
glucose monitoring, insulin injection
technique, insulin storage, recognition/
treatment of hypoglycemia, and “sick
day” rules is imperative. Where available,
certiﬁed diabetes educators can be in-
valuable in guiding the patient through
this process.
Implementation strategies
Initial drug therapy. It is generally
agreed that metformin, if not contraindi-
cated and if tolerated, is the preferred and
most cost-effective ﬁrst agent (42) (Fig. 2
and Supplementary Figs.). It is initiated at,
or soon after, diagnosis, especially in pa-
tients in whom lifestyle intervention alone
has not achieved, or is unlikely to achieve,
HbA1c goals. Because of frequent gastroin-
testinal side effects, it should be started at a
low dose with gradual titration. Patients
with a high baseline HbA1c (e.g., $9.0%)
have a low probability of achieving a near-
normal target with monotherapy. It may
therefore be justiﬁed to start directly
with a combination of two noninsulin
agents or with insulin itself in this circum-
stance (78). If a patient presents with sig-
niﬁcant hyperglycemic symptoms and/or
has dramatically elevated plasma glucose
concentrations (e.g., .16.7–19.4 mmol/L
[.300–350 mg/dL]) or HbA1c (e.g.,
$10.0–12.0%), insulin therapy should be
strongly considered from the outset. Such
treatment is mandatory when catabolic
features are exhibited or, of course, if
ketonuria is demonstrated, the latter re-
ﬂecting profound insulin deﬁciency. Im-
portantly, unless there is evidence of type 1
diabetes, once symptoms are relieved,
glucotoxicity resolved, and the metabolic
state stabilized, it may be possible to taper
insulin partially or entirely, transferring to
noninsulin antihyperglycemic agents, per-
haps in combination.
If metformin cannot be used, another
oral agent could be chosen, such as a
sulfonylurea/glinide, pioglitazone, or a
DPP-4 inhibitor; in occasional cases where
weight loss is seen as an essential aspect of
therapy, initial treatment with a GLP-1
receptor agonist might be useful. Where
available, less commonly used drugs (AGIs,
colesevelam, bromocriptine) might also be
considered in selected patients, but their
modest glycemic effects and side-effect
proﬁles make them less attractive candi-
dates. Speciﬁc patient preferences, char-
acteristics, susceptibilities to side effects,
potential for weight gain and hypoglycemia
should play a major role in drug selection
(20,21). (See Supplementary Figs. for ad-
aptations of Fig. 2 that address speciﬁc
patient scenarios.)
Advancing to dual combination therapy.
Figure 2 (and Supplementary Figs.) also
depicts potential sequences of escalating
glucose-lowering therapy beyond met-
formin. If monotherapy alone does not
achieve/maintain an HbA1c target over
;3 months, the next step would be to
add a second oral agent, a GLP-1 recep-
tor agonist, or basal insulin (5,10). No-
tably, the higher the HbA1c, the more
likely insulin will be required. On average,
any second agent is typically associated
with an approximate further reduction in
HbA1c of ;1% (70,79). If no clinically
meaningful glycemic reduction (i.e., “non-
responder”) is demonstrated, then, adher-
ence having been investigated, that agent
should be discontinued, and another
with a different mechanism of action
substituted. With a distinct paucity of
long-term comparative-effectiveness trials
available, uniform recommendations on
the best agent to be combined with metfor-
min cannot bemade (80). Thus, advantages
and disadvantages of speciﬁc drugs for each
patient should be considered (Table 1).
Some antihyperglycemic medications
lead to weight gain. This may be associ-
ated with worsening markers of insulin
resistance and cardiovascular risk. One
exception may be TZDs (57); weight gain
associated with this class occurs in asso-
ciation with decreased insulin resistance.
Although there is no uniform evidence that
increases in weight in the range observed
with certain therapies translate into a sub-
stantially increased cardiovascular risk, it
remains important to avoid unnecessary
KEY POINTS
c Glycemic targets and glucose-lowering
therapies must be individualized.
c Diet, exercise, and education remain
the foundation of any type 2diabetes
treatment program.
c Unless there are prevalent contra-
indications, metformin is the op-
timal ﬁrst-line drug.
c After metformin, there are limited
data to guide us. Combination
therapywith an additional 1–2 oral
or injectable agents is reasonable,
aiming to minimize side effects
where possible.
c Ultimately, many patients will require
insulin therapy alone or in com-
bination with other agents to
maintain glucose control.
c All treatment decisions, where possi-
ble, should be made in conjunction
with the patient, focusing on his/her
preferences, needs, and values.
c Comprehensive cardiovascular risk
reduction must be a major focus of
therapy.
1370 DIABETES CARE, VOLUME 35, JUNE 2012 care.diabetesjournals.org
Position Statement
weight gain by optimal medication selec-
tion and dose titration.
For all medications, consideration
should also be given to overall tolerability.
Even occasional hypoglycemia may be
devastating, if severe, or merely irritating,
if mild (81). Gastrointestinal side effects
may be tolerated by some, but not others.
Fluid retention may pose a clinical or
merely an aesthetic problem (82). The
risk of bone fracturesmay be a speciﬁc con-
cern in postmenopausal women (57).
It must be acknowledged that costs
are a critical issue driving the selection of
glucose-lowering agents in many environ-
ments. For resource-limited settings, less
expensive agents should be chosen. How-
ever, due consideration should be also
given to side effects and any necessary
monitoring, with their own cost impli-
cations. Moreover, prevention of morbid
Figure 2dAntihyperglycemic therapy in type 2 diabetes: general recommendations. Moving from the top to the bottom of the ﬁgure, potential
sequences of antihyperglycemic therapy. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis
(unless there are explicit contraindications). If the HbA1c target is not achieved after;3months, consider one of the ﬁve treatment options combined
with metformin: a sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, or basal insulin. (The order in the chart is determined by historical
introduction and route of administration and is notmeant to denote any speciﬁc preference.) Choice is based on patient and drug characteristics, with
the over-riding goal of improving glycemic control while minimizing side effects. Shared decision making with the patient may help in the selection of
therapeutic options. The ﬁgure displays drugs commonly used both in the U.S. and/or Europe. Rapid-acting secretagogues (meglitinides) may be
used in place of sulfonylureas. Other drugs not shown (a-glucosidase inhibitors, colesevelam, dopamine agonists, pramlintide) may be used where
available in selected patients but have modest efﬁcacy and/or limiting side effects. In patients intolerant of, or with contraindications for, metformin,
select initial drug from other classes depicted and proceed accordingly. In this circumstance, while published trials are generally lacking, it is
reasonable to consider three-drug combinations other than metformin. Insulin is likely to be more effective than most other agents as a third-line
therapy, especially when HbA1c is very high (e.g., $9.0%). The therapeutic regimen should include some basal insulin before moving to more
complex insulin strategies (Fig. 3). Dashed arrow line on the left-hand side of the ﬁgure denotes the option of a more rapid progression from a two-
drug combination directly to multiple daily insulin doses, in those patients with severe hyperglycemia (e.g., HbA1c$10.0–12.0%). DPP-4-i, DPP-4
inhibitor; Fx’s, bone fractures; GI, gastrointestinal; GLP-1-RA, GLP-1 receptor agonist; HF, heart failure; SU, sulfonylurea. aConsider beginning at this
stage in patients with very high HbA1c (e.g.,$9%).
bConsider rapid-acting, nonsulfonylurea secretagogues (meglitinides) in patients with irregular
meal schedules or who develop late postprandial hypoglycemia on sulfonylureas. cSee Table 1 for additional potential adverse effects and risks, under
“Disadvantages.” dUsually a basal insulin (NPH, glargine, detemir) in combination with noninsulin agents. eCertain noninsulin agents may be
continued with insulin (see text). Refer to Fig. 3 for details on regimens. Consider beginning at this stage if patient presents with severe hyperglycemia
($16.7–19.4 mmol/L [$300–350 mg/dL]; HbA1c $10.0–12.0%) with or without catabolic features (weight loss, ketosis, etc.).
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long-term complications will likely reduce
long-termexpenses attributed to thedisease.
Advancing to triple combination ther-
apy. Some studies have shown advantages
of adding a third noninsulin agent to a
two-drug combination that is not yet or
no longer achieving the glycemic target
(83–86). Not surprisingly, however, at
this juncture, the most robust response
will usually be with insulin. Indeed, since
diabetes is associated with progressive
b-cell loss, many patients, especially those
with long-standing disease, will eventually
need to be transitioned to insulin, which
should be favored in circumstances where
the degree of hyperglycemia (e.g., $8.5%)
makes it unlikely that another drug will be
of sufﬁcient beneﬁt (87). If triple combina-
tion therapy exclusive of insulin is tried, the
patient should be monitored closely, with
the approach promptly reconsidered if it
proves to be unsuccessful. Many months
of uncontrolled hyperglycemia should
speciﬁcally be avoided.
In using triple combinations the es-
sential consideration is obviously to use
agents with complementary mechanisms
of action (Fig. 2 and Supplementary Figs.).
Increasing the number of drugs heightens
the potential for side effects and drug–drug
interactions, raises costs, and negatively im-
pacts patient adherence. The rationale, ben-
eﬁts, and side effects of each newmedication
should be discussed with the patient. The
clinical characteristics of patients more or
less likely to respond to speciﬁc combina-
tions are, unfortunately, not well deﬁned.
Transitions to and titrations of insulin.
Most patients express reluctance to be-
ginning injectable therapy, but, if the
practitioner feels that such a transition is
important, encouragement and education
can usually overcome such reticence. In-
sulin is typically begun at a low dose (e.g.,
0.1–0.2 U kg21 day21), although larger
amounts (0.3–0.4 U kg21 day21) are rea-
sonable in the more severely hyperglyce-
mic. The most convenient strategy is
with a single injection of a basal insulin,
with the timing of administration depen-
dent on the patient’s schedule and overall
glucose proﬁle (Fig. 3).
Although extensive dosing instruc-
tions for insulin are beyond the scope of
this statement, most patients can be taught
to uptitrate their own insulin dose based
on several algorithms, each essentially in-
volving the addition of a small dose increase
if hyperglycemia persists (74,76,88). For
example, the addition of 1–2 units (or, in
those already on higher doses, increments
of 5–10%) to the daily dose once or twice
weekly if the fasting glucose levels are above
the preagreed target is a reasonable ap-
proach (89). As the target is neared, dosage
adjustments should be more modest and
occur less frequently. Downward adjust-
ment is advisable if any hypoglycemia oc-
curs. During self-titration, frequent contact
(telephone, e-mail) with the clinician may
be necessary. Practitioners themselves can,
of course, also titrate basal insulin, but this
would involve more intensive contact with
the patient than typically available in rou-
tine clinical practice. Daily self-monitoring
of blood glucose is of obvious importance
during this phase. After the insulin dose is
stabilized, the frequency of monitoring
should be reviewed (90).
Consideration should be given to the
addition of prandial or mealtime insulin
coverage when signiﬁcant postprandial
glucose excursions (e.g., to.10.0 mmol/L
[.180 mg/dL]) occur. This is suggested
when the fasting glucose is at target but
the HbA1c remains above goal after 3–6
months of basal insulin titration (91). The
same would apply if large drops in glucose
occur during overnight hours or in be-
tween meals, as the basal insulin dose is
increased. In this scenario, the basal insulin
dose would obviously need to be simulta-
neously decreased as prandial insulin is ini-
tiated. Although basal insulin is titrated
primarily against the fasting glucose, gen-
erally irrespective of the total dose, practi-
tioners should be aware that the need for
prandial insulin therapywill become likely the
more the daily dose exceeds 0.5 U kg21
day21, especially as it approaches 1 U kg21
day21. The aim with mealtime insulin is to
blunt postprandial glycemic excursions,
Figure 3dSequential insulin strategies in type 2 diabetes. Basal insulin alone is usually the
optimal initial regimen, beginning at 0.1–0.2 units/kg body weight, depending on the degree of
hyperglycemia. It is usually prescribed in conjunction with one to two noninsulin agents. In
patients willing to takemore than one injection andwho have higher HbA1c levels ($9.0%), twice-
daily premixed insulin or a more advanced basal plus mealtime insulin regimen could also be
considered (curved dashed arrow lines). When basal insulin has been titrated to an acceptable
fasting glucose but HbA1c remains above target, consider proceeding to basal plus mealtime in-
sulin, consisting of one to three injections of rapid-acting analogs (see text for details). A less
studied alternativedprogression from basal insulin to a twice-daily premixed insulindcould be
also considered (straight dashed arrow line); if this is unsuccessful, move to basal plus mealtime
insulin. Theﬁgure describes the number of injections required at each stage, togetherwith the relative
complexity and ﬂexibility. Once a strategy is initiated, titration of the insulin dose is important, with
dose adjustments made based on the prevailing glucose levels as reported by the patient. Noninsulin
agents may be continued, although insulin secretagogues (sulfonylureas, meglitinides) are typically
stopped once more complex regimens beyond basal insulin are utilized. Comprehensive education
regarding self-monitoring of blood glucose, diet, exercise, and the avoidance of, and response to,
hypoglycemia are critical in any patient on insulin therapy. Mod., moderate.
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which can be extreme in some individuals,
resulting in poor control during the day.
Such coverage may be provided by one of
two methods.
The most precise and ﬂexible prandial
coverage is possible with “basal-bolus”
therapy, involving the addition of premeal
rapid-acting insulin analog to ongoing
basal insulin. One graduated approach
is to add prandial insulin before the
meal responsible for the largest glucose
excursiondtypically that with the greatest
carbohydrate content, often, but not always,
the evening meal (92). Subsequently, a sec-
ond injection can be administered before the
meal with the next largest excursion (often
breakfast). Ultimately, a third injectionmay
be added before the smallest meal (often
lunch) (93). The actual glycemic beneﬁts
of these more advanced regimens after
basal insulin are generallymodest in typical
patients (92). So, again, individualization
of therapy is key, incorporating the degree
of hyperglycemia needing to be ad-
dressed and the overall capacities of the
patient. Importantly, data trends from
self-monitoring may be particularly help-
ful in titrating insulins and their doses
within these more advanced regimens to
optimize control.
A second, perhaps more convenient
but less adaptable method involves “pre-
mixed” insulin, consisting of a ﬁxed com-
bination of an intermediate insulin with
regular insulin or a rapid analog. Tradi-
tionally, this is administered twice daily,
before morning and evening meals. In
general, when compared with basal insu-
lin alone, premixed regimens tend to
lower HbA1c to a larger degree, but often
at the expense of slightly more hypogly-
cemia and weight gain (94). Disadvan-
tages include the inability to titrate the
shorter- from the longer-acting compo-
nent of these formulations. Therefore,
this strategy is somewhat inﬂexible but
may be appropriate for certain patients
who eat regularly and may be in need
of a simpliﬁed approach beyond basal in-
sulin (92,93). (An older and less commonly
used variation of this two-injection strategy
is known as “split-mixed,” involving a ﬁxed
amount of intermediate insulin mixed by
the patient with a variable amount of regu-
lar insulin or a rapid analog. This allows for
greater ﬂexibility in dosing.)
The key messages from dozens of
comparative insulin trials in type 2 diabetes
include the following:
1. Any insulin will lower glucose and
HbA1c.
2. All insulins are associated with some
weight gain and some risk of hypo-
glycemia.
3. The larger the doses and the more
aggressive the titration, the lower the
HbA1c, but often with a greater likeli-
hood of adverse effects.
4. Generally, long-acting insulin analogs
reduce the incidence of overnight hy-
poglycemia, and rapid-acting insulin
analogs reduce postprandial glucose
excursions as compared with corre-
sponding human insulins (NPH, Reg-
ular), but they generally do not result in
clinically signiﬁcantly lower HbA1c.
Metformin is often continued when
basal insulin is added, with studies dem-
onstrating less weight gain when the two
are used together (95). Insulin secretago-
gues do not seem to provide for additional
HbA1c reduction or prevention of hypo-
glycemia or weight gain after insulin is
started, especially after the dose is titrated
and stabilized. When basal insulin is
used, continuing the secretagogue may
minimize initial deterioration of glycemic
control. However, secretagogues should
be avoided once prandial insulin regi-
mens are employed. TZDs should be re-
duced in dose (or stopped) to avoid
edema and excessive weight gain, al-
though in certain individuals with large
insulin requirements from severe insulin
resistance, these insulin sensitizers may be
very helpful in lowering HbA1c and mini-
mizing the required insulin dose (96).
Data concerning the glycemic beneﬁts of
incretin-based therapy combined with
basal insulin are accumulating; combina-
tion with GLP-1 receptor agonists may be
helpful in some patients (97,98). Once
again, the costs of these more elaborate
combined regimens must be carefully
considered.
OTHER CONSIDERATIONS
Age
Older adults (.65–70 years) often have a
higher atherosclerotic disease burden, re-
duced renal function, and more comor-
bidities (99,100). Many are at risk for
adverse events from polypharmacy and
may be both socially and economically
disadvantaged. Life expectancy is reduced,
especially in the presence of long-term
complications. They are also more likely
to be compromised by hypoglycemia; for
example, unsteadiness may result in falls
and fractures (101), and a tenuous cardiac
status may deteriorate into catastrophic
events. It follows that glycemic targets for
elderly with long-standing or more com-
plicated disease should be less ambitious
than for the younger, healthier individuals
(20). If lower targets cannot be achieved
with simple interventions, an HbA1c of
,7.5–8.0% may be acceptable, transition-
ing upward as age increases and capacity
for self-care, cognitive, psychological and
economic status, and support systems
decline.
While lifestyle modiﬁcation can be
successfully implemented across all age-
groups, in the aged, the choice of anti-
hyperglycemic agent should focus on
drug safety, especially protecting against
hypoglycemia, heart failure, renal dys-
function, bone fractures, and drug–drug
interactions. Strategies speciﬁcally mini-
mizing the risk of low blood glucose may
be preferred.
In contrast, healthier patients with
long life expectancy accrue risk for vas-
cular complications over time. Therefore,
lower glycemic targets (e.g., an HbA1c
,6.5–7.0%) and tighter control of body
weight, blood pressure, and circulating
lipids should be achieved to prevent or
delay such complications. This usually re-
quires combination therapy, the early in-
stitution of which may have the best
chance of modifying the disease process
and preserving quality of life.
Weight
The majority of individuals with type 2
diabetes are overweight or obese (;80%)
(102). In these, intensive lifestyle inter-
vention can improve ﬁtness, glycemic
control, and cardiovascular risk factors
for relatively small changes in body
weight (103). Although insulin resistance
is thought of as the predominate driver of
diabetes in obese patients, they actually
have a similar degree of islet dysfunction
to leaner patients (37). Perhaps as a result,
the obese may be more likely to require
combination drug therapy (20,104).
While common practice has favored met-
formin in heavier patients, because of
weight loss/weight neutrality, this drug
is as efﬁcacious in lean individuals (75).
TZDs, on the other hand, appear to be
more effective in those with higher BMIs,
although their associated weight gain
makes them, paradoxically, a less attractive
option here. GLP-1 receptor agonists are
associated with weight reduction (38),
which in some patients may be substantial.
Bariatric surgery is an increasingly
popular option in severe obesity. Type 2
diabetes frequently resolves rapidly after
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these procedures. Themajority of patients
are able to stop some, or even all, of their
antihyperglycemic medications, although
the durability of this effect is not known
(105).
In lean patients, consideration should
be given to the possibility of latent autoim-
mune diabetes in adults (LADA), a slowly
progressive form of type 1 diabetes. These
individuals, while presenting with mild
hyperglycemia, often responsive to oral
agents, eventually develop more severe
hyperglycemia and require intensive insu-
lin regimens (106).Measuring titres of islet-
associated autoantibodies (e.g., anti-GAD)
may aid their identiﬁcation, encouraging a
more rapid transition to insulin therapy.
Sex/racial/ethnic/genetic differences
While certain racial/ethnic features that
increase the risk of diabetes are well recog-
nized [greater insulin resistance in Latinos
(107), more b-cell dysfunction in East
Asians (108)], using this information to
craft optimal therapeutic strategies is in its
infancy. This is not surprising given the
polygenic inheritance pattern of the dis-
ease. Indeed, while matching a drug’s
mechanism of action to the underlying
causes of hyperglycemia in a speciﬁc patient
seems logical, there are few data that com-
pare strategies based on this approach
(109). There are few exceptions, mainly
involving diabetes monogenic variants of-
ten confused with type 2 diabetes, such as
maturity-onset diabetes of the young
(MODY), several forms of which respond
preferentially to sulfonylureas (110).
While there are no prominent sex differ-
ences in the response to various antihyper-
glycemic drugs, certain side effects (e.g.,
bone loss with TZDs) may be of greater
concern in women.
Comorbidities
Coronary artery disease. Given the fre-
quency with which type 2 diabetic patients
develop atherosclerosis, optimal manage-
ment strategies for thosewith or at high risk
for coronary artery disease (CAD) are
important. Since hypoglycemia may ex-
acerbate myocardial ischemia and may
cause dysrhythmias (111), it follows that
medications that predispose patients to
this adverse effect should be avoided, if
possible. If they are required, however, to
achieve glycemic targets, patients should
be educated to minimize risk. Because of
possible effects on potassium channels in
the heart, certain sulfonylureas have been
proposed to aggravate myocardial ischemia
through effects on ischemic preconditioning
(112), but the actual clinical relevance of this
remains unproven. Metformin may have
some cardiovascular beneﬁts and would
appear to be a useful drug in the setting
of CAD, barring prevalent contraindica-
tions (32). In a single study, pioglitazone
was shown to reduce modestly major ad-
verse cardiovascular events in patients
with established macrovascular disease.
It may therefore also be considered, unless
heart failure is present (60). In very pre-
liminary reports, therapy with GLP-1 re-
ceptor agonists and DPP-4 inhibitors has
been associated with improvement in ei-
ther cardiovascular risk or risk factors, but
there are no long-term data regarding clin-
ical outcomes (113). There are very limited
data suggesting that AGIs (114) and bromo-
criptine (115) may reduce cardiovascular
events.
Heart failure. With an aging population
and recent decreases in mortality after
myocardial infarction, the diabetic patient
with progressive heart failure is an in-
creasingly common scenario (116). This
population presents unique challenges
given their polypharmacy, frequent hos-
pitalizations, and contraindications to
various agents. TZDs should be avoided
(117,118). Metformin, previously contra-
indicated in heart failure, can now be used
if the ventricular dysfunction is not se-
vere, if patient’s cardiovascular status is
stable, and if renal function is normal
(119). As mentioned, cardiovascular ef-
fects of incretin-based therapies, includ-
ing those on ventricular function, are
currently under investigation (120).
Chronic kidney disease. Kidney disease
is highly prevalent in type 2 diabetes, and
moderate to severe renal functional im-
pairment (eGFR ,60 mL/min) occurs in
approximately 20–30% of patients
(121,122). The individual with progres-
sive renal dysfunction is at increased risk
for hypoglycemia, which is multifactorial.
Insulin and, to some degree, the incretin
hormones are eliminated more slowly, as
are antihyperglycemic drugs with renal
excretion. Thus, dose reduction may be
necessary, contraindications need to be
observed, and consequences (hypoglyce-
mia, ﬂuid retention, etc.) require careful
evaluation.
Current U.S. prescribing guidelines
warn against the use of metformin in
patients with a serum creatinine $133
mmol/L ($1.5 mg/dL) in men or 124
mmol/L ($1.4 mg/dL) in women. Metfor-
min is eliminated renally, and cases of lactic
acidosis have been described in patients
with renal failure (123). There is an
ongoing debate, however, as to whether
these thresholds are too restrictive and
that those with mild–moderate renal im-
pairment would gain more beneﬁt than
harm from using metformin (124,125). In
the U.K., the National Institute for Health
and Clinical Excellence (NICE) guidelines
are less proscriptive and more evidence-
based than those in the U.S., generally al-
lowing use down to a GFR of 30 mL/min,
with dose reduction advised at 45 mL/min
(14). Given the current widespread report-
ing of estimated GFR, these guidelines
appear very reasonable.
Most insulin secretagogues undergo
signiﬁcant renal clearance (exceptions in-
clude repaglinide and nateglinide) and
the risk of hypoglycemia is therefore
higher in patients with chronic kidney
disease (CKD). For most of these agents,
extreme caution is imperative atmore severe
degrees of renal dysfunction. Glyburide
(known as glibenclamide in Europe),
which has a prolonged duration of
action and active metabolites, should
be speciﬁcally avoided in this group.
Pioglitazone is not eliminated renally, and
therefore there are no restrictions for use
in CKD. Fluid retention may be a concern,
however. Among the DPP-4 inhibitors,
sitagliptin, vildagliptin, and saxagliptin
share prominent renal elimination. In the
face of advanced CKD, dose reduction is
necessary. One exception is linagliptin,
which is predominantly eliminated enter-
ohepatically. For the GLP-1 receptor ago-
nists exenatide is contraindicated in stage
4–5 CKD (GFR ,30 mL/min) as it is re-
nally eliminated; the safety of liraglutide is
not established in CKD though pharmaco-
kinetic studies suggest that drug levels are
unaffected as it does not require renal func-
tion for clearance.
More severe renal functional impair-
ment is associated with slower elimina-
tion of all insulins. Thus doses need to be
titrated carefully, with some awareness
for the potential for more prolonged
activity proﬁles.
Liver dysfunction. Individuals with type
2 diabetes frequently have hepatosteatosis
as well as other types of liver disease
(126). There is preliminary evidence that
patients with fatty liver may beneﬁt from
treatment with pioglitazone (45,127,128).
It should not be used in an individual with
active liver disease or an alanine transami-
nase level above 2.5 times the upper limit of
normal. In those with steatosis but milder
liver test abnormalities, this insulin sensi-
tizer may be advantageous. Sulfonylureas
can rarely cause abnormalities in liver tests
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but are not speciﬁcally contraindicated;
meglitinides can also be used. If hepatic
disease is severe, secretagogues should be
avoided because of the increased risk of
hypoglycemia. In patients with mild he-
patic disease, incretin-based drugs can be
prescribed, except if there is a coexisting
history of pancreatitis. Insulin has no re-
strictions for use in patients with liver im-
pairment and is indeed the preferred choice
in those with advanced disease.
Hypoglycemia. Hypoglycemia in type 2
diabetes was long thought to be a trivial
issue, as it occurs less commonly than in
type 1 diabetes. However, there is emerg-
ing concern based mainly on the results
of recent clinical trials and some cross-
sectional evidence of increased risk of
brain dysfunction in those with repeated
episodes. In the ACCORD trial, the fre-
quency of both minor and major hypo-
glycemia was high in intensively managed
patientsdthreefold that associated with
conventional therapy (129). It remains
unknown whether hypoglycemia was
the cause of the increased mortality in
the intensive group (130,131). Clearly,
however, hypoglycemia is more danger-
ous in the elderly and occurs consistently
more often as glycemic targets are low-
ered. Hypoglycemia may lead to dys-
rhythmias, but can also lead to accidents
and falls (which are more likely to be dan-
gerous in the elderly) (132), dizziness
(leading to falls), confusion (so other ther-
apies may not be taken or taken incor-
rectly), or infection (such as aspiration
during sleep, leading to pneumonia). Hy-
poglycemia may be systematically under-
reported as a cause of death, so the true
incidence may not be fully appreciated.
Perhaps just as importantly, additional con-
sequences of frequent hypoglycemia in-
clude work disability and erosion of the
conﬁdence of the patient (and that of family
or caregivers) to live independently. Accord-
ingly, in at-risk individuals, drug selection
should favor agents that do not precipitate
such events and, in general, blood glucose
targets may need to be moderated.
FUTURE DIRECTIONS/
RESEARCH NEEDSdFor antihyper-
glycemic management of type 2 diabetes,
the comparative evidence basis to date is
relatively lean, especially beyond metfor-
minmonotherapy (70). There is a signiﬁcant
need for high-quality comparative-
effectiveness research, not only regarding
glycemic control, but also costs and those
outcomes that matter most to patientsd
quality of life and the avoidance of morbid
and life-limiting complications, especially
CVD (19,23,70). Another issue about which
more data are needed is the concept of du-
rability of effectiveness (often ascribed to
b-cell preservation), which would serve
to stabilize metabolic control and decrease
the future treatment burden for patients.
Pharmacogenetics may very well inform
treatment decisions in the future, guiding
the clinician to recommend a therapy for an
individual patient based on predictors of
response and susceptibility to adverse ef-
fects. We need more clinical data on how
phenotype and other patient/disease char-
acteristics should drive drug choices. As
new medications are introduced to the
type 2 diabetes pharmacopeia, their beneﬁt
and safety should be demonstrated in stud-
ies versus best current treatment, substan-
tial enough both in size and duration to
provide meaningful data on meaningful
outcomes. It is appreciated, however, that
head-to-head comparisons of all combina-
tions and permutations would be impossi-
bly large (133). Informed judgment and the
expertise of experienced clinicians will
therefore always be necessary.
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